Alexion is a pharmaceutical company based in Boston, MA that specializes in the development and production of therapeutic medications. Their flagship product, ULTOMIRIS, is a medication used for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. ULTOMIRIS offers predictable maintenance dosing with as few as 6 to 7 infusions per year after an initial loading dose, and has been proven to deliver improvement in activities of daily living for patients with gMG.
As a leader in the field of immunization, Alexion also emphasizes the importance of vaccination in patients receiving ULTOMIRIS. They comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies, and provide comprehensive support and resources for healthcare professionals and patients alike. With a focus on safety and efficacy, Alexion is dedicated to improving the lives of individuals with gMG and other medical conditions through their innovative medications and patient-centered approach.
Generated from the website